# Xiuning Le

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/xiuning-le/

## Facts

| Field | Value |
| --- | --- |
| Citations | 11,973 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 52 |
| i10-index | 129 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5007462622 |
| ORCID iD | 0000-0002-8554-1185 |
| Works | 469 |

## Researcher papers

- [Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations](https://scholariq.org/papers/tepotinib-in-non-small-cell-lung-cancer-with-i-met-i-exon-14-skipping-mutations/)
- [Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial](https://scholariq.org/papers/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-operable-non-small-cell/)
- [Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance](https://scholariq.org/papers/pan-cancer-t-cell-atlas-links-a-cellular-stress-response-state-to-immunotherapy/)
- [Structure-based classification predicts drug response in EGFR-mutant NSCLC](https://scholariq.org/papers/structure-based-classification-predicts-drug-response-in-egfr-mutant-nsclc/)
- [Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy](https://scholariq.org/papers/molecular-mechanisms-and-future-implications-of-vegf-vegfr-in-cancer-therapy/)
- [Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i> -Mutant NSCLC](https://scholariq.org/papers/landscape-of-egfr-dependent-and-independent-resistance-mechanisms-to-osimertinib/)
- [Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer](https://scholariq.org/papers/comprehensive-analysis-of-genetic-ancestry-and-its-molecular-correlates-in/)
- [Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC](https://scholariq.org/papers/dual-egfr-vegf-pathway-inhibition-a-promising-strategy-for-patients-with-egfr/)
- [Effects of RAS on the genesis of embryonal rhabdomyosarcoma](https://scholariq.org/papers/effects-of-ras-on-the-genesis-of-embryonal-rhabdomyosarcoma/)
- [Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer](https://scholariq.org/papers/oncogene-specific-differences-in-tumor-mutational-burden-pd-l1-expression-and/)
- [Abstract 7166: Spatially resolved protein profiling of tumor and immune microenvironment in EGFR mutant NSCLC with transformation to SCLC](https://scholariq.org/papers/abstract-7166-spatially-resolved-protein-profiling-of-tumor-and-immune/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.